11 Best M&A Advisors in San Diego for $5M-$300M Deals (2026)

11 Best M&A Advisors in San Diego for $5M-$300M Deals (2026)

Quick answer: San Diego-metro sellers at $5M to $300M EV pick advisors against three structural deal engines: biotech (densest US cluster after Boston and SF Bay), defense and dual-use (General Atomics, Northrop, Cubic, Shield AI), and wireless/semis (Qualcomm-led). The 11 anchor firms are Objective Investment Banking & Valuation, RA Capital Advisors, W Partners, Shoreline Partners, LR Tullius, Henberger Group, SeaRidge Advisory, Stout SD, Generational Group SD, BroadOak Capital Partners, and Corporate Finance Associates Worldwide. The 2026 market backdrop is Novartis's $13.7B SD biotech M&A in 12 months plus a $23B US expansion with an SD research hub, Merck-Cidara $9.2B, AbbVie-Capstan $2.1B, Neurocrine-Soleno $2.9B, Qualcomm-Alphawave $2.4B, and Shield AI's $12.7B valuation.

The 11 anchor firms split into three structural lanes. SD-anchored boutiques — Objective Investment Banking & Valuation (Carmel Valley, Channing Hamlet + Trever Acers, 500+ M&A engagements, Best IB & Valuation Firm 2025 USA), RA Capital Advisors (San Diego since 1988, Joel Weinstein 20+ years + Jeff Dittmer), W Partners (Todd D. Wilson, family-office focus), Shoreline Partners (since 1992, Tim Malott + John Reynolds), LR Tullius (Lance Tullius, 200+ transactions, $3B+ aggregate), Henberger Group, and SeaRidge Advisory (up to $100M EV). National-platform offices — Stout SD (opened 2022 via Vantage Point acquisition) and Generational Group SD (opened April 2024). Sub-vertical specialists — BroadOak Capital Partners (life sciences only) and Corporate Finance Associates Worldwide. The structural test for advisor selection is sub-vertical fit (biotech vs defense vs wireless vs lower-mm) plus the Strategic Acquirer Density Premium — SD's same-city strategic-buyer concentration is structurally higher than any US metro outside Boston and SF Bay.

San Diego has gone from a regional biotech and defense market to a structural buyer-pool capital between 2024 and 2026. Four biotech mega-deals in 12 months — Avidity $12B, Cidara $9.2B, Soleno $2.9B, Capstan $2.1B — totaling $26.2B in SD-target biotech M&A make this one of the most active US biotech sell-side windows on record. Qualcomm's $2.4B Alphawave acquisition (December 2025) plus Shield AI's $12.7B valuation (March 2026) extend the cluster into wireless / semis and defense. The combination produces a deal-flow environment where the right SD-anchored advisor with strategic-acquirer relationships compresses time-to-close materially compared to a generalist regional bank.

I have built and watched thousands of data rooms across my career — about 1,000 of those when I was an investor at two funds with a combined $6.3 billion in AUM, and the rest across the 8,000+ teams Peony serves today, where the founders we work with have raised over $18 billion to date. SD-metro sell-side teams running processes at $5M-$300M EV are a meaningful slice of that customer base. This guide is the working map of who's strong in which sub-vertical, what the buyer pool composition actually looks like, and which advisors run the cleanest processes in 2026 — including how it compares against our work mapping the Phoenix, LA, SF, Seattle, and Boston M&A advisor landscapes.

What's the 2026 San Diego M&A backdrop, and why does it matter for advisor selection?

Three structural forces converged in 2025-26 that change SD-metro M&A in 2026:

1. The Novartis $13.7B SD biotech wave + $23B US expansion. Novartis paid $12B for Avidity Biosciences (announced October 26, 2025; $72 per share at 46 percent premium for RNA neuromuscular platform covering DMD, DM1, FSHD) and $1.7B for Regulus Therapeutics (closed June 25, 2025; $7 per share plus $7 CVR for RNA kidney platform including farabursen for ADPKD). The $13.7B from a single strategic acquirer to SD biotech targets in 12 months — combined with Novartis's April 2025 announcement of a $23B US expansion that includes a new SD research hub — repositions every SD biotech founder with a late-stage neuro / RNA / rare-disease asset as a theoretical Novartis target.

2. The four-deal biotech mega-wave. Beyond the two Novartis transactions, Merck paid $9.2B for Cidara Therapeutics (announced November 14, 2025, $221.50 per share for antiviral CD388), AbbVie paid $2.1B for Capstan Therapeutics (closed August 19, 2025, in vivo CAR-T CPTX2309 with Centerview Partners as Capstan financial advisor and Cooley legal), and Neurocrine Biosciences paid $2.9B for Soleno Therapeutics (announced April 6, 2026, $53 per share at 34 percent premium for Prader-Willi VYKAT XR — Neurocrine's largest M&A ever and the first SD-on-SD strategic combination in 2026). Together, $26.2B in SD-target biotech sell-side M&A in 12 months — no comparable US metro produced this concentration.

3. The Qualcomm + Shield AI cluster acceleration. Qualcomm closed its $2.4B Alphawave Semi acquisition December 18, 2025 (UK chip designer with chiplet IP and high-speed serial connectivity), alongside Ventana Micro Systems (December 2025) and Arduino (October 2025). Shield AI raised a $2B total ($1.5B Series G common equity + $500M Blackstone fixed-return preferred, plus a $250M loan facility) at $12.7B valuation March 26, 2026 (Advent International + JPMorganChase Security and Resiliency Initiative as Series G co-leads), making it the most valuable SD defense-tech company. Shield AI's pending acquisition of Aechelon Technology (South San Francisco; flight and synthetic reality simulation) was announced alongside the Series G. General Atomics tucked in MLD Technologies in August 2025.

Frame: The Strategic Acquirer Density Premium. Three US metros have the structural property that a founder's most likely strategic buyer is headquartered in the same city: Boston (biotech / pharma), SF Bay Area (software / AI), and San Diego (biotech / wireless / defense). In SD, the local strategic-buyer roster includes Illumina, Qualcomm, Neurocrine, Crinetics Pharmaceuticals, ResMed, Tandem Diabetes, General Atomics, and Shield AI. An advisor that knows the local corp-dev teams personally compresses the buyer-outreach phase by 4-8 weeks compared to an out-of-market firm rebuilding those relationships from scratch. This is materially different from Phoenix (mostly out-of-state buyers) or LA (entertainment industry dominates).

Which 11 verified M&A advisors actually cover San Diego in 2026?

The 11 firms below split into three structural lanes: SD-anchored boutiques (Objective, RA Capital, W Partners, Shoreline, LR Tullius, Henberger, SeaRidge), national-platform offices (Stout, Generational), and sub-vertical specialists (BroadOak for life sciences, CFAW for cross-border). Decision logic: at $5M-$100M EV, an SD-anchored boutique with sub-vertical match is typically the right answer; at $100M-plus on biotech or defense, the dual-mandate structure (SD boutique + specialty-tech-tier bank) is the 2026 default.

1. Objective Investment Banking & Valuation

• HQ: 11622 El Camino Real, Suite 100, San Diego, CA 92130 (Carmel Valley)
• Lead bankers: Channing Hamlet (Founder & Managing Director, leads Life Sciences & Business Services practice; previously at Cabrillo Advisors, LLR Partners, Legg Mason; Cornell BS/MS), Trever F. Acers (Managing Director, San Diego Business Journal "500 Most Influential Business Leaders" five consecutive years, UCLA Anderson MBA, USD undergrad)
• Sector focus: Business Services, Consumer, Healthcare Tech & Services, Life Sciences Services & Tech, Manufacturing & Distribution, Technology (four formal practices)
• Deal size range: $25M-$300M middle market
• Scale: 14 professionals (one of the largest SD-headquartered M&A teams)
• Recognition: 500+ M&A engagements completed; Best Investment Bank & Valuation Firm 2025 USA; Cross-Border Deal of the Year ($100MM-$1B) 2024
• LA expansion: Opened Century City office; now bi-coastal Southern California
• Why hire them: Largest SD-anchored team with formal sub-vertical practices. Strongest at $25M-$200M generalist middle market where Hamlet and Acers run buyer calls personally and the team can carry parallel processes.

2. RA Capital Advisors

• HQ: San Diego, CA (founded 1988 — one of the longest-running SD-headquartered M&A boutiques)
• Lead bankers: Joel Weinstein (Managing Director; 20+ years of M&A advisory experience; previously co-founding partner at W Partners, PwC TICE practice in NY and SD; Tulane finance), Jeff Dittmer (Managing Director, sell-side M&A with focus on founder/family-owned businesses)
• Sector focus: Multi-industry — consumer, healthcare, industrials, technology
• Deal size range: Middle market to Fortune 500 advisory (estimated $25M-$500M band)
• Services: M&A, private financings, shareholder matters, restructurings, crisis situations
• Credentials: FINRA member firm (BrokerCheck 40992); 37-year SD presence
• Why hire them: Deepest SD biotech-veteran HNW capital relationships (3-plus decades of placing private-owner transactions with La Jolla / Rancho Santa Fe family offices). Discreet process style suits founder-family-owned exits.

3. W Partners

• HQ: San Diego, CA + Utah office
• Lead: Todd D. Wilson (Partner; co-founder with Joel Weinstein and Wickham; Weinstein later moved to RA Capital)
• Sector focus: Consumer, healthcare, industrials, technology (broad sector platform)
• Deal size range: Middle market
• Founded: 2009
• Distinctive positioning: Explicitly targets middle-market companies and family offices in the Western U.S. — one of the few SD M&A firms with stated family-office orientation
• Why hire them: Family-office-channel access plus Western-US footprint. Stronger fit for owner-operator exits to HNW or family-office capital than to strategic buyers.

4. Shoreline Partners

• HQ: San Diego, CA — founded 1992 (one of the longest-running SD M&A boutiques)
• Lead bankers: Phil Currie (Founder; passed away late 2025, active until then), Tim Malott (Managing Partner; former CPA + national bank president; joined 1994 as partner, took Managing Partner role in 2017), John Reynolds (Partner since 2023; joined as Managing Director 2020)
• Sector focus: Generalist — cross-industry sell-side M&A for private owners
• Deal size range: Lower middle market
• Credentials: FINRA broker-dealer affiliate (ShorelineAmbrose Advisors)
• Why hire them: 33-year SD presence with deepest historical local relationships. Strong on private-owner exits across cross-industry verticals where the buyer pool is mostly domestic PE and family office.

5. LR Tullius

• HQ: 10920 Via Frontera, Suite 450, San Diego, CA 92127 (Rancho Bernardo)
• Founder: Lance Tullius (20+ years M&A advisory; 200+ career transactions, $3B+ aggregate value)
• Sector focus: Lower middle market with notable depth in consumer services and pest control sub-sector
• Deal size range: Lower middle market (estimated $5M-$50M)
• Track record: 32 firm deals to date (28 M&A + 4 funding) per Tracxn January 2026
• Founded: 2014
• Why hire them: Strongest SD boutique for consumer services and pest control sub-vertical. Lance Tullius's 200-plus career transactions provide deep buyer-network reach at the lower end.

6. Henberger Group

• HQ: San Diego, CA
• Sector focus: Emerging-growth and lower middle market, including family-owned companies with explicit exit-planning and transition focus
• Deal size range: Lower middle market
• Why hire them: Best fit for exit-planning-driven sell-sides where the founder needs a 12-24 month preparation window. Smaller boutique scale means more senior-banker attention per mandate.

7. SeaRidge Advisory

• HQ: 4231 Balboa Ave, San Diego, CA 92117 (Clairemont/Kearny Mesa)
• Sector focus: Manufacturing, engineering, professional services, healthcare, finance (operates several specialized brand verticals under one parent)
• Deal size range: Up to $100M enterprise value (lower middle market)
• Distinctive positioning: Self-described "lower–middle market M&A and business brokerage firm" — bridges between business broker and IB advisor models
• Why hire them: Right fit for SD-metro sellers in the $5M-$50M EV band who want a hybrid IB-plus-broker process structure with multiple sub-brand verticals.

8. Stout (San Diego office)

• SD office opened: 2022 (Stout's 26th global office) following acquisition of San Diego-based Vantage Point Advisors
• Firm HQ: Chicago
• Sector focus: Industry-focused bankers across multiple verticals; M&A advisory, private capital raising, special situations / distressed M&A
• Deal size range: Middle market
• Why hire them: SD's youngest national-platform M&A office with the deepest local tech-banking DNA inherited from the Vantage Point acquisition. Strongest at $50M-$300M middle market where Stout's industry-vertical depth and complex-situations expertise add value.

9. Generational Group (San Diego office)

• SD regional office: 9655 Granite Ridge Drive Suite 200, San Diego, CA 92123 (Kearny Mesa); opened April 2024
• Firm HQ: Dallas (Generational, founded 2005)
• Sector focus: Generalist sell-side advisory for owner-led lower-middle-market across all sectors
• Deal size range: Lower-mid market to mid market
• Scale: 350-plus professionals nationally
• Services: M&A, strategic growth advisory, exit planning, business valuation, wealth management
• Why hire them: Largest national platform with a dedicated SD office. National buyer-pool reach without bulge-bracket cost structure. Strong for owner-operator exits at $5M-$100M EV.

10. BroadOak Capital Partners (SF Bay Area-based, SD portfolio coverage)

• HQ: Bethesda, MD + Brisbane, CA (SF Bay Area)
• SD coverage: Bay-Area-based but actively covers SD life sciences targets from the Brisbane office given proximity and SD's dominant life sciences cluster
• Sector focus: Life sciences tools, diagnostics, biopharma services (exclusively)
• Track record: 75+ investments and 50+ M&A transactions advised
• Deal size range: Life-sciences-focused middle market sell-side
• Capital position: $200M+ in permanent capital added in 2021 with subsequent platform expansion through 2024-25
• Why hire them: The dominant Bay-Area-anchored sub-vertical specialist for pure-play life sciences tools, diagnostics, and biopharma services covering SD targets. For SD biotech founders with a sub-vertical fit, BroadOak's depth in the specific buyer pool (Danaher, Thermo Fisher, Illumina, Agilent, Bio-Rad, Waters, PerkinElmer) outweighs broader generalist coverage even without an SD-dedicated office.

11. Corporate Finance Associates Worldwide (CFAW — San Diego practice)

• SD practice: Serves Southern California; firm 70+ years old with ~30 offices globally
• Sector focus: Technology, healthcare, transport, financial services, distribution, manufacturing
• Notes: Senior-principal-driven local engagements with large national/international back-end network
• Why hire them: Strongest at cross-border sell-sides where international buyer outreach matters and the SD seller wants global coverage without bulge-bracket cost structure.

Honorable mentions covered from out-of-state platforms: Houlihan Lokey, Lincoln International, and Centerview Partners cover SD-area deals from broader LA / SF / NY platforms but did not surface dedicated SD M&A offices in current sources. Decision pattern: at $5M-$100M, SD-anchored boutiques typically beat out-of-state platforms; at $100M-plus biotech or defense deals, the specialty-tech-tier banks (Centerview, Cantor Fitzgerald Healthcare, MTS Health Partners, Qatalyst for tech) are usually the right co-advisor pairing with an SD-anchored boutique for the dual-mandate structure visible in Capstan-AbbVie.

Note on Cabrillo Advisors: Founded 2006 originally in San Diego; acquired by Crete Professionals Alliance in August 2025. No longer an independent SD M&A boutique. Channing Hamlet, its former Managing Director, now leads Objective Investment Banking & Valuation.

The San Diego Buyer-Pool Quadrant — who's actually buying?

Frame: The San Diego Buyer-Pool Quadrant. SD-metro sellers face a four-quadrant buyer pool that diverges sharply from generic US mid-market patterns. The compositional difference: SD's strategic-acquirer concentration is structurally higher than any US metro outside Boston and SF Bay, and the same-city strategic acquirer is often the highest-probability buyer.

The four-quadrant cut matters for advisor selection: an SD biotech founder targeting NW (global pharma strategic) plus SE (APAC pharma corp-dev) needs different buyer outreach than an SD defense supplier targeting only NE (defense primes) plus SW (defense-cleared PE platforms). Boutiques with vertical relationships in 2-3 quadrants typically outperform platform firms running broader but shallower outreach. For the cross-quadrant case where a single asset spans biotech + global pharma + APAC + domestic PE (typical for late-stage SD biotech), the dual-mandate structure (SD-anchored boutique + specialty-tech-tier bank) is the standard 2026 pattern.

How does the Novartis Overhang reshape SD biotech advisor selection?

The Strategic Acquirer Density Premium is sharpest in SD biotech — Illumina and Neurocrine are SD-HQ corp-dev targets a local advisor can reach faster than an out-of-market firm rebuilding relationships from scratch. Novartis sits on top of that local layer as the most-active 2025-26 inbound strategic acquirer.

Frame: The Novartis Overhang. After Novartis paid $13.7B for two SD biotechs in 12 months and committed $23B to a new US expansion that includes an SD research hub, every SD biotech founder with a late-stage neuro / RNA / rare-disease asset is now a theoretical Novartis target. In the SD biotech rooms I have reviewed across the past 12 months, the dominant pattern is sell-side advisors front-running a Novartis read in week 3-4 of the process rather than waiting for the broader buyer pool to settle. This changes the advisor-selection calculus in three specific ways:

1. Speed of Novartis read. Advisor firms that have already placed transactions with Novartis (BroadOak's life-sciences specialization, plus the dual-mandate structure with Centerview / Cantor / MTS) can establish a Novartis corp-dev read in 4-6 weeks. Generalist firms typically need 8-12 weeks for the same. In a competitive process where four strategics (Novartis + Merck + AbbVie + Pfizer or Roche) are pitching against each other, that 4-8 week gap can be the difference between competitive auction premium and bilateral negotiation.

2. Conflict scan. Any firm currently engaged on a Novartis mandate (advising Novartis on a different acquisition, or representing Novartis-acquired Avidity or Regulus in a follow-on) creates structural conflict on your asset. The conflict scan is a standard fact pattern for any biotech engagement letter but takes on new weight when Novartis is one of 4 likely buyers rather than one of 20.

3. Platform-thesis filter understanding. Novartis's $13.7B in SD acquisitions in 2025-26 was concentrated on RNA modalities (Avidity, Regulus) and rare disease — not random biotech assets. Advisors who understand the Novartis platform-thesis filter (RNA modality, kidney + neuro + neuromuscular, rare-disease orientation, late-stage clinical readouts within 18 months) can position SD biotech assets against the filter rather than spraying generic pitch decks at Novartis corp-dev.

Recommended advisor pattern for SD biotech founders contemplating a Novartis-targeted exit: combine BroadOak Capital Partners (or another life-sciences specialist with deep tools / diagnostics / biopharma services depth) with a specialty-tech-tier bank (Centerview Partners — which advised Capstan in the AbbVie deal — or Cantor Fitzgerald Healthcare or MTS Health Partners). Add an SD-anchored generalist boutique (Objective IB&V or RA Capital) for senior-banker face-time on local diligence and family-office channel coordination. The triple-mandate is unusual but increasingly common at $500M-plus deal sizes. The mid-cluster comparison sits in our biotech M&A data room setup guide, which maps the document-pack differences for SD founders running this dual-mandate playbook against Boston Cambridge biotech where the cluster is more academic-research-anchored.

How wide is the Cleared Advisor Gap in SD defense and dual-use M&A?

Frame: The Cleared Advisor Gap. SD defense and dual-use deals (General Atomics ecosystem, Shield AI vendors, Cubic supplier base, Northrop Grumman tier 2-3 suppliers) frequently touch ITAR / CFIUS / Secret / SCI-cleared personnel. The gap: most generalist SD M&A firms (Objective, Shoreline, LR Tullius, Henberger, SeaRidge, W Partners) do not staff cleared bankers. For SD defense sellers, the practical decision tree:

1. Sub-$25M EV with no ITAR-classified IP: SD generalist boutique is usually fine. SeaRidge, LR Tullius, or Shoreline can cover. The buyer pool is usually domestic PE platforms or family offices that do not require defense clearances.

2. $25M-$100M EV with ITAR exposure but limited CFIUS sensitivity: Stout's SD office (Vantage Point DNA) or Generational Group SD plus a national platform IB (Raymond James, Stifel, Baird) for buyer-pool depth. The right pattern is a co-advisor structure where the SD boutique covers process management and the national platform covers buyer outreach to ITAR-cleared strategic buyers.

3. $100M-$300M EV with CFIUS notification requirement: Specialist defense IB (KippsDeSanto, Renaissance Strategic Advisors, Capstone Partners Aerospace & Defense, McLean Group) or specialty-tech-tier bank (Baird, Lazard's defense practice, Houlihan Lokey defense team from broader LA/SF). The CFIUS notification process is a separate workstream that requires advisor experience with CFIUS counsel coordination — typically 6-8 weeks of process work parallel to the buyer-outreach phase.

4. Dual-use AI or simulation tech with CFIUS sensitivity: The Shield AI / Anduril / Palantir-class playbook. Advisor selection should test the firm's track record on dual-use deals specifically (not pure-defense and not pure-commercial). Shield AI's pending acquisition of Aechelon Technology in March 2026 is the most recent SD precedent.

For SD defense sellers, the right test of any pitching advisor: ask for 2 named closed defense-cleared transactions in the past 36 months with deal-size band. Firms that cannot answer specifically are likely overselling the lane.

How does the IPO-Strategic Fork shape SD biotech advisor selection in 2026?

Frame: The IPO-Strategic Fork. Q1 2026 biopharma raised $1.7 billion in IPOs — the most of any quarter since 2021 — with a $287.5M median raise per BioPharma Dive's Q1 2026 IPO report. That figure compares against the $2B-plus strategic exit prices on late-stage SD biotechs (Avidity $12B / Cidara $9.2B / Capstan $2.1B / Regulus $1.7B). SD biotech founders face a real choice between an IPO with $200M-$500M proceeds and continued operational independence, or a strategic exit at 2-10x the IPO valuation but with company-ending optionality.

Advisor selection signals which path a founder is committing to. Bulge-bracket capital-markets bookrunners (Morgan Stanley, JPMorgan, Jefferies, Cowen) cluster on the IPO path through their ECM teams; strategic-exit specialists (Centerview Partners, Cantor Fitzgerald Healthcare, MTS Health Partners, plus BroadOak for sub-$1B life sciences) cluster on the M&A path. A small sector-specialist boutique can run either, but rarely both well. The structural read on the November 2024-May 2026 window: every SD biotech exit greater than $2B has been a strategic acquisition, not an IPO follow-on. The IPO path is now a financing event for platform builders (multi-asset companies with durable IP), not an exit event for single-asset founders. For SD biotech founders pre-Phase 3 or with single-asset platforms, the M&A path typically wins on risk-adjusted return; for platform-thesis assets with multiple programs and validated mechanisms, the IPO path preserves optionality at the cost of execution risk.

What does the San Diego M&A deal cadence look like over the past 12 months?

A sampling of SD-metro deals in the May 2025 to May 2026 window:

Pattern read: 2025-26 SD deal flow was dominated by (a) biotech mega-deals concentrated on RNA modalities and rare-disease assets (Avidity, Regulus, Capstan, Cidara, Soleno), (b) Qualcomm's wireless / semi consolidation cadence (Alphawave, Ventana, Arduino), (c) Shield AI's defense-tech ascent ($12.7B valuation plus pending Aechelon acquisition), and (d) Illumina's life-sciences-tools strategy (SomaLogic). The Strategic Acquirer Density Premium is most visible in the same-city HQ concentration: Qualcomm, Illumina, Neurocrine, Shield AI, General Atomics all SD-HQ means SD founders see different buyer dynamics than equivalent founders in non-cluster cities — the local advisor with established corp-dev relationships is structurally more valuable than the out-of-market platform brand.

What underpins the San Diego M&A buyer-pool composition?

San Diego-metro data points that underpin M&A buyer-pool composition:

• Life sciences ecosystem: 1,400+ life science companies in the San Diego region (part of Biocom California's 1,700+ statewide membership); 71,448 direct life science jobs in SD; $54.1B total economic output for the SD region per BIOCOM California 2025 Life Sciences Economic Impact Report
• Life sciences employment growth: 12.3 percent (2022-2023 period), ranked #1 in the US per CBRE 2025 US Life Sciences Outlook
• Biotech venture activity: ~$4.8B raised across 180+ deals in 2025; 3rd-largest US biotech cluster after Boston/Cambridge and SF Bay Area per BIOCOM California / Business of San Diego
• Total SD venture/M&A deal count: ~152 closed deals in 2025, down 6 percent YoY from 161 (selective rather than retrenching market)
• Defense / aerospace ecosystem: General Atomics (largest SD defense contractor), Northrop Grumman, Cubic, BAE Systems, General Dynamics NASSCO, Shield AI ($12.7B valuation), plus Naval Base San Diego anchor
• Wireless / semi ecosystem: Qualcomm headquarters; multiple Qualcomm spinouts and supplier-network firms; UCSD wireless research depth
• Research-institution density: UCSD, Scripps Research Institute, Salk Institute, Sanford Burnham Prebys Medical Discovery Institute concentrated within ~10 miles of each other in La Jolla — the densest US research triangle outside Boston/Cambridge

The compounding effect: SD's research-institution density feeds the biotech and tools / diagnostics startup pipeline; the strategic-acquirer concentration (Illumina, Qualcomm, Neurocrine, General Atomics, Shield AI all HQ in SD) provides the same-city buyer pool; the La Jolla / Rancho Santa Fe / Carmel Valley HNW concentration provides the family-office capital channel; and the defense / dual-use ecosystem provides a structurally separate but locally concentrated second deal engine.

Which data room is right for a San Diego M&A process?

San Diego sell-side processes at $5M-$300M EV typically need: multi-party permissioning (for 15-40 buyer parties across biotech strategic / PE / family-office / defense-cleared segments), NDA gating with executed-NDA verification, dynamic watermarking for confidential biotech IP and CFIUS-sensitive defense documents, and page-level analytics for buyer engagement verification.

The honest landscape:

We make Peony, so this is honest disclosure: for $200M-plus biotech or CFIUS-sensitive defense deals (the Avidity-Novartis $12B class), most counsel will recommend Datasite or Intralinks. For sub-$100M SD processes — which by deal count includes most lower-middle-market services exits, defense supplier tuck-ins, life-sciences sub-platform deals, and family-office-channel transactions — the flat-rate options (Peony, Firmex, Ansarada) typically deliver equivalent functionality at substantially lower transaction cost. For SD biotech founders specifically: Peony's per-recipient watermarks and page-level analytics support the 15-40-buyer parallel-outreach pattern that biotech sell-sides require, and the $52/admin/month flat pricing scales without per-page upload overage that hits biotech rooms harder than generalist M&A rooms (typical SD biotech room: 8,000-15,000 pages of clinical / preclinical / IP / quality / manufacturing documentation).

For a deeper teardown, see our virtual data room pricing guide.

Related resources

• Best M&A Advisors: the 49-city and 24-sector directory — the national hub this guide belongs to: route by geography, sector and deal size before you shortlist
• M&A advisor vs business broker vs investment bank — the decision that comes before this San Diego shortlist: which of the three intermediary types should sell your company, by deal size, goal, and the licensing line that separates them
• M&A advisor fees: what you actually pay — the fee hub for this series: Lehman vs Double Lehman math, retainer credits, minimum-fee floors, and the engagement-letter clauses that inflate the bill
• 11 Best M&A Advisors in Phoenix — Tier A US comparator with semis + aerospace cluster
• 11 Best M&A Advisors in Seattle — Tier A US comparator with Microsoft / AWS / Boeing buyer-pool
• 11 Best M&A Advisors in Boston — biotech / Cambridge cluster comparator
• 11 Best M&A Advisors in San Francisco — Bay Area tech / biotech comparator
• 11 Best M&A Advisors in LA — Southern California comparator
• Best M&A Advisors in Las Vegas — Southwest comparator where gaming deals close twice: at signing and at the Gaming Control Board
• Biotech M&A Data Room Setup (2026) — sub-vertical data-room playbook for SD biotech founders
• M&A Due Diligence Process Guide — process map across all DD layers
• Sell-Side Due Diligence — VDD for SD sellers preparing for process
• Virtual Data Room Pricing Guide — full vendor landscape
• Best data room for small M&A — VDR selection for sub-$30M sell-sides, the band that covers most SD lower-middle-market services exits, defense supplier tuck-ins, and family-office-channel deals where per-page Datasite billing is uneconomic